2-Butenal


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0001836 Release of cytochrome c from mitochondria Increases phenotype PMID:23535401
GO:0002523 Leukocyte migration involved in inflammatory response Increases phenotype PMID:33749501
GO:0004069 L-aspartate:2-oxoglutarate aminotransferase activity Increases phenotype PMID:33749501
GO:0004129 Cytochrome-c oxidase activity Decreases phenotype PMID:33749501
GO:0004784 Superoxide dismutase activity Decreases phenotype PMID:33749501
GO:0006309 Apoptotic dna fragmentation Increases phenotype PMID:23535401
GO:0006749 Glutathione metabolic process Affects phenotype PMID:33749501
GO:0006750 Glutathione biosynthetic process Decreases phenotype PMID:23535401
GO:0006915 Apoptotic process Increases phenotype PMID:23535401; PMID:31345100; PMID:33749501
GO:0007005 Mitochondrion organization Decreases phenotype PMID:33749501
GO:0008121 Ubiquinol-cytochrome-c reductase activity Decreases phenotype PMID:33749501
GO:0008137 Nadh dehydrogenase (ubiquinone) activity Decreases phenotype PMID:33749501
GO:0008177 Succinate dehydrogenase (ubiquinone) activity Decreases phenotype PMID:33749501
GO:0008284 Positive regulation of cell population proliferation Increases phenotype PMID:32634517
GO:0009055 Electron transfer activity Decreases phenotype PMID:33749501
GO:0010460 Positive regulation of heart rate Increases phenotype PMID:32634517
GO:0019229 Regulation of vasoconstriction Affects phenotype PMID:32320793
GO:0030263 Apoptotic chromosome condensation Increases phenotype PMID:33749501
GO:0032774 Rna biosynthetic process Affects phenotype PMID:33749501
GO:0042221 Response to chemical Increases phenotype PMID:32634517
GO:0042310 Vasoconstriction Increases phenotype PMID:32320793
GO:0042632 Cholesterol homeostasis Decreases phenotype PMID:32634517
GO:0044237 Cellular metabolic process Decreases phenotype PMID:31166132
GO:0045776 Negative regulation of blood pressure Increases phenotype PMID:32634517
GO:0045907 Positive regulation of vasoconstriction Increases phenotype PMID:32634517
GO:0046034 Atp metabolic process Affects phenotype PMID:33749501
GO:0046466 Membrane lipid catabolic process Increases phenotype PMID:30426860; PMID:31345100
GO:0070328 Triglyceride homeostasis Decreases phenotype PMID:32634517
GO:0070527 Platelet aggregation Affects phenotype PMID:32634517
GO:0072593 Reactive oxygen species metabolic process Increases phenotype PMID:23535401; PMID:33749501
GO:1903409 Reactive oxygen species biosynthetic process Increases phenotype PMID:31345100
GO:1905144 Response to acetylcholine Increases phenotype PMID:32634517
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.